Table 1.

Perfusion-cardiovascular magnetic resonance and stress dobutamine-cardiovascular magnetic resonance: diagnostic performance

Study	n (n)	Reference	CM type/dose	Stress	Analysis	Sensitivity	Specificity	AUC
Perfusion-CMR
Single6	57	CXA (≥50%)	Gd-DTPA-BMA/0.1 mmol/kg	Dip (stress only)	Upslope subendo	87	85	0.91
Single6	43	PET (CFR)	Gd-DTPA-BMA/0.1 mmol/kg	Dip (stress only)	Upslope subendo	91	94	0.93
Single7	92	CXA (≥70%)	Gd-DTPA/0.05 mmol/kg	Adeno (rest/stress)	Upslope PRI	88	82	0.91
Single8	79	CXA (≥50%)	Gd-BOPTA/0.05 mmol//kg	Adeno (stress/rest)	Visual	91	62	—
Single14	84	CXA (≥75%)a	Gd-DTPA/0.025 mmol/kg	Adeno (rest/stress)	Upslope PRI	86	87	0.92
Single15	104	CXA (≥70%)	Gd-DTPA/0.75 mmol/kg	Dip (stress/rest)	Visual	90	85	0.90
Single9	51	CXA (≥50%)	Gadobutrol/0.1 mmol/kg	Adeno (stress only)	Visual	—	—	0.85
Multicentre16	50	CXA (≥50%)	Gd-DTPA/0.05 mmol/kg	ATP (stress/rest)	Visual	86	75	0.88
Multicentre12	80 (24)	CXA (≥50%)	Gd-DTPA-BMA/0.1 mmol/kg	Adeno (stress only)	Upslope subendo	91	78	0.91
Low dose12	80 (29)	CXA (≥50%)	Gd-DTPA-BMA/0.05 mmol/kg	Adeno (stress only)	Upslope subendo	—	—	0.53
MR-IMPACT10	212 (42)	CXA (≥50%)	Gd-DTPA-BMA/0.075 mmol/kg	Adeno (stress only)	Visual	85	67	0.86
Stress dobutamine-CMR
Single29	186	CXA (≥50%)	—	Dobutamine	Visual	86	86	—
Single30	41b	CXA (≥50%)	—	Dobutamine	Visual	83	83	—
Single31	22	CXA (≥75%)a	—	Dobutamine	Visual	88	83	—
Single32	27	CXA (≥70%)	—	Treadmill	Visual	79	85	—
Single8	79	CXA (≥50%)	—	Dobutamine	Visual	89	80	—
Single23c	150	CXA (≥50%)	—	Dobutamine	Visual	78	87	—
Single33	40	CXA (≥50%)	—	Dobutamine	Visual	89	75	—
Single34	204d	CXA (≥70%)	—	Dobutamine	Visual	85	86	—

n: in CM dose-finding studies (n) indicates participants in a specific dose group; PRI, perfusion reserve index.

^aArea stenosis.

^bPatients with negative dobutamine-CMR: CXA was not performed, but a follow-up of 6 months, where no cardiac death occurred.

^cReproducibility study: for sensitivity and specificity, means are given.

^dWomen only.